Arcutis Biotherapeutics, Inc. (ARQT)
NASDAQ: ARQT · Real-Time Price · USD
10.18
+0.09 (0.89%)
Nov 20, 2024, 4:00 PM EST - Market closed
Arcutis Biotherapeutics Employees
Arcutis Biotherapeutics had 296 employees as of December 31, 2023. The number of employees increased by 28 or 10.45% compared to the previous year.
Employees
296
Change (1Y)
28
Growth (1Y)
10.45%
Revenue / Employee
$468,608
Profits / Employee
-$660,591
Market Cap
1.19B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 296 | 28 | 10.45% |
| Dec 31, 2022 | 268 | 121 | 82.31% |
| Dec 31, 2021 | 147 | 93 | 172.22% |
| Dec 31, 2020 | 54 | 25 | 86.21% |
| Dec 31, 2019 | 29 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Tilray Brands | 2,650 |
| Artivion | 1,500 |
| Maravai LifeSciences Holdings | 650 |
| CareDx | 643 |
| Progyny | 566 |
| Aurinia Pharmaceuticals | 300 |
| Rocket Pharmaceuticals | 268 |
| Ardelyx | 267 |
ARQT News
- 5 days ago - Arcutis Biotherapeutics: +200% On ZORYVE Approval, But When Is The Next Leg Up? - Seeking Alpha
- 14 days ago - Arcutis Biotherapeutics, Inc. (ARQT) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 14 days ago - Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 16 days ago - Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Conference - GlobeNewsWire
- 4 weeks ago - Top 3 Health Care Stocks That Could Lead To Your Biggest Gains In Q4 - Benzinga
- 4 weeks ago - Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older - GlobeNewsWire
- 2 months ago - New Data Shows ZORYVE® (Roflumilast) Cream 0.15% Provided Consistent Improvement of Atopic Dermatitis in Individuals With Diverse Skin Types - GlobeNewsWire